Following grant of patent in Europe in November 2023 for the company’s mutant TGFbR2 vaccine technology platform, we are happy to announce that patents now have been granted also in Hong Kong and Mexico. Jon Amund Eriksen, CEO and founder of Hubro Bioscience said, “These new patents are important additions to Hubro Bioscience’s intellectual property portfolio covering our vaccine technology for prevention of hereditary cancer in high-risk risk population Lynch Syndrome. The patents further extend the protection of the lead vaccine candidate FMPV3.”
